Drug Approval | February 19, 2022
Amneal expands injectables portfolio with four new products
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Agilent will integrate the technology into its lab informatics platforms, enabling customers to automate GC/MS data analysis
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
Through this acquisition, Ayu Health will add 1000 beds to provide localised primary and tertiary medical care for citizens of Jaipur
The entire integration and transition of the brands is expected to be completed by March 2022
Expected to open later this year, the facility will significantly increase distribution capacity to meet the growing demand for production materials by Ireland's biopharma industry
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Subscribe To Our Newsletter & Stay Updated
